In LARC, ten studies explored association of pre-CRT Hb levels with tumor response after CRT [22,24,25,26,29,30,32,41,52,58]; one study considered post-CRT Hb levels [41], and one considered Hb variation during treatment [32]. The gene discussed is GSTM1; the disease is neoplasm.